查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1914542

白血病藥物市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、性別、年齡層、診斷、治療方法、藥物、給藥途徑、地區和競爭格局分類），2021-2031年

Leukemia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Gender, By Age Groups, By Diagnosis, By Treatment, By Drugs, By Route of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球白血病治療市場預計將從2025年的165.1億美元成長到2031年的269.5億美元，複合年成長率（CAGR）為8.51%。這些治療方法涵蓋多種醫療干預措施，包括化療、免疫療法、標靶治療和幹細胞移植，所有這些療法都旨在對抗起源於造血組織（例如骨髓）的惡性腫瘤。推動該市場成長的關鍵因素是全球血液癌症發病率的不斷上升以及人口老化導致老年人更容易患上這些疾病，從而直接催生了對有效藥物解決方案的需求。例如，美國癌症協會估計，2024年美國將新增62,770例白血病病例，凸顯了需要治療的患者數量龐大。

市場概覽
預測期 2027-2031
市場規模：2025年 165.1億美元
市場規模：2031年 269.5億美元
複合年成長率：2026-2031年 8.51%
成長最快的細分市場 免疫療法
最大的市場 北美洲

儘管市場成長勢頭強勁，但由於新型療法的高昂成本，市場仍面臨許多障礙。先進治療方法，特別是基因修飾細胞療法和個人化生技藥品，定價過高，對醫療預算造成巨大壓力，限制了患者的獲得，尤其是在發展中地區。這種高昂的經濟門檻，加上嚴格的報銷政策，對限制這些藥物的廣泛應用構成了重大挑戰，並可能阻礙整體市場擴張。

市場促進因素

強大的臨床研發管線和加速的藥物核准是市場擴張的關鍵驅動力，同時，針對骨髓惡性腫瘤抗藥性問題的新作用機制也不斷湧現。製藥公司正迅速推進下一代藥物（例如menin抑制劑和雙特異性抗體）從臨床試驗到商業化的進程。這項創新蘊含著巨大的經濟潛力。例如，2025年11月，諾華公司將其靶向白血病藥物Scemblix的尖峰時段銷售預期上調至至少40億美元，這反映了該藥物良好的臨床前景所帶來的巨大商業性價值。此外，監管機構正透過加速核准途徑來促進這一成長，以滿足未被滿足的醫療需求。 2025年11月，美國FDA核准了Kura Oncology公司的Comzifti（diftomenib）用於治療復發/難治性急性骨髓性白血病，這標誌著精準癌症治療領域的一項重大進展。

同時，全球急性和慢性白血病發病率的上升是推動治療性介入。這些癌症的盛行率不斷上升，尤其是在人口老化的情況下，使得全球迫切需要有效的長期管理策略。近期的預測也印證了這日益加重的疾病負擔。美國癌症協會估計，光是2025年1月，美國就將新增66,890例白血病病例，凸顯了確保患者獲得治療的重要性。患者數量的增加迫使醫療系統擴大化療和免疫療法的採購，從而推動市場成長，並刺激對該領域的進一步投資。

市場挑戰

全球白血病治療市場面臨的一大挑戰是新型治療方法，特別是基因修飾細胞療法和個人化生物製藥的高成本。儘管這些醫療干預措施能帶來顯著的臨床效益，但其高昂的定價結構卻構成了阻礙其廣泛應用的巨大經濟障礙。醫療系統和保險公司往往難以負擔這些高昂的費用，導致報銷保單僵化、承保範圍受限。因此，經濟壓力迫使支付方限制只有少數合格的患者才能獲得治療，從而縮小了藥物研發者的目標市場規模，並減緩了這些藥物的商業性化進程。

近期先進免疫療法的定價數據凸顯了這個障礙的經濟規模。根據美國癌症協會預測，到2025年，光是CAR-T細胞療法產品的成本就將達到30萬至47.5萬美元，而每位患者的總治療費用往往超過50萬美元。如此龐大的支出給醫療預算帶來了沉重負擔，尤其是在醫療基礎設施資源匱乏的地區。因此，這種由成本驅動的治療障礙阻礙了更多有需要的患者獲得治療，從而有效地抑制了市場擴張。

市場趨勢

雙特異性T細胞銜接（BiTE）療法的應用日益廣泛，從根本上改變了治療格局。它提供了一種即用型免疫療法，避免了自體細胞療法複雜的物流和生產延遲。與患者特異性CAR-T療法不同，BiTE療法可即時用於急性白血病患者，從而促進其快速商業性化應用，並整合到復發和難治性惡性腫瘤的標準治療通訊協定中。其主要藥物強勁的市場表現支撐了這種快速的臨床應用。根據安進公司2024年10月發布的2024年第三季財報，該公司雙特異性T細胞銜接劑Brincito的銷售額達到3.27億美元，年成長49%，主要得益於銷量的顯著成長。這項進展標誌著市場正發生決定性轉變，即採用易於取得的雙特異性療法作為治療侵襲性B細胞前驅細胞的首選治療方法。

同時，對微量殘存疾病（MRD）監測和治療的日益重視，正將患者管理從簡單的症狀控制轉變為深度分子緩解策略。臨床醫生擴大使用高靈敏度的次世代定序技術來檢測傳統形態學評估無法發現的白血病細胞痕跡，並利用這些結果來指南關於停止或加強治療的精準決策。這種對診斷方法的日益依賴在近期的使用指標中得到了體現。根據Adaptive Biotechnologies公司於2024年11月發布的“2024年第三季財報”，該公司clonoSEQ MRD檢測的臨床測試數量年增30%，達到約19,600例。這一快速成長支持了白血病治療市場向生物標記定義的終點轉變，旨在最佳化長期生存率並最大限度地減少不必要的毒性。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球白血病藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（慢性淋巴性白血病、急性骨髓性白血病、慢性骨髓性白血病、急性淋巴性白血病、其他）
    • 性別（男，女）
    • 依年齡層別（0-15歲、15-30歲、30-50歲、50歲以上）
    • 透過診斷方法（血液檢查、切片檢查、身體檢查、影像診斷）
    • 治療方法（化療、幹細胞移植、免疫療法、標靶治療、其他）
    • 依藥物類型（蛋白酪氨酸激酶抑制劑、代謝拮抗劑、荷爾蒙（皮質類固醇）、單株抗體、其他）
    • 給藥途徑（口服、注射）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美白血病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲白血病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區白血病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲白血病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲白血病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球白血病藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Bristol-Myers Squibb Company
  • AstraZeneca Plc
  • Gilead Sciences Inc.
  • Pfizer Inc,
  • F. Hoffmann-La Roche AG
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Applied Molecular Genetics Inc.
  • Regeneron Pharmaceuticals, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 4534

The Global Leukemia Therapeutics Market is projected to expand from USD 16.51 Billion in 2025 to USD 26.95 Billion by 2031, achieving a CAGR of 8.51%. These therapeutics comprise a wide range of medical interventions, including chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation, all aimed at fighting malignancies that originate in blood-forming tissues such as bone marrow. A primary catalyst for this market is the growing global incidence of hematologic cancers alongside an aging population that is increasingly prone to these conditions, creating a direct demand for effective pharmaceutical solutions. For instance, the American Cancer Society estimated that 62,770 new leukemia cases were diagnosed in the United States in 2024, highlighting the substantial volume of patients requiring treatment.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 16.51 Billion
Market Size 2031USD 26.95 Billion
CAGR 2026-20318.51%
Fastest Growing SegmentImmunotherapy
Largest MarketNorth America

Despite this positive growth trajectory, the market encounters significant obstacles due to the exorbitant costs associated with novel treatments. Advanced therapies, particularly genetically modified cell therapies and personalized biologics, are priced at levels that burden healthcare budgets and restrict patient access, especially in developing regions. This high financial barrier, combined with strict reimbursement policies, presents a major challenge that limits the widespread adoption of these drugs and has the potential to impede the overall expansion of the market.

Market Driver

A robust clinical pipeline and accelerated drug approvals serve as the primary engines for market expansion, consistently introducing novel mechanisms to address resistance in hematological malignancies. Pharmaceutical developers are rapidly advancing next-generation agents, including menin inhibitors and bispecific antibodies, from clinical trials to commercial availability. This innovation is underscored by significant financial potential; for instance, Novartis raised its peak sales forecast for the targeted leukemia drug Scemblix to at least $4 billion in November 2025, reflecting the immense commercial value of superior clinical profiles. Furthermore, regulatory bodies are facilitating this growth through expedited pathways for unmet needs, as seen in November 2025 when the U.S. FDA approved Kura Oncology's Komzifti (ziftomenib) for relapsed or refractory acute myeloid leukemia, marking a major advancement in precision oncology.

Simultaneously, the rising global incidence of acute and chronic leukemia acts as a fundamental driver of demand, necessitating the sustained consumption of therapeutic interventions. The increasing prevalence of these cancers, particularly within an expanding geriatric population, generates an urgent volume-based need for effective long-term management strategies worldwide. This escalating disease burden is evident in recent projections; the American Cancer Society estimated in January 2025 that 66,890 new leukemia cases would be diagnosed in the United States alone, emphasizing the critical necessity for accessible treatments. This growing patient pool compels healthcare systems to increase their procurement of chemotherapies and immunotherapies, thereby supporting the market's upward trajectory and incentivizing further investment in the sector.

Market Challenge

The primary challenge directly hindering the Global Leukemia Therapeutics Market is the prohibitive cost of novel treatment modalities, especially genetically modified cell therapies and personalized biologics. While these medical interventions offer substantial clinical benefits, their steep pricing structures create high financial barriers that restrict widespread adoption. Healthcare systems and insurance providers frequently struggle to absorb these elevated expenses, resulting in stringent reimbursement policies and limited coverage determinations. Consequently, economic pressures force payers to restrict access to a smaller subset of eligible patients, thereby reducing the addressable market volume for pharmaceutical developers and slowing the commercial uptake of these drugs.

The financial magnitude of this barrier is illustrated by recent pricing data for advanced immunotherapies. According to the American Cancer Society in 2025, the cost for CAR T-cell therapy products alone ranged between $300,000 and $475,000, with the total cost of care frequently exceeding $500,000 per patient. Such substantial expenditures place a severe strain on healthcare budgets, particularly in regions with resource-constrained medical infrastructure. As a result, this cost-driven inaccessibility effectively hampers the market's expansion by preventing these therapies from reaching the broader patient population that requires them.

Market Trends

The expansion of Bispecific T-Cell Engager (BiTE) applications is fundamentally reshaping the treatment landscape by offering off-the-shelf immunotherapies that avoid the complex logistics and manufacturing delays associated with autologous cell therapies. Unlike patient-specific CAR-T regimens, BiTEs provide immediate accessibility for acute leukemia cases, driving rapid commercial uptake and integration into standard treatment protocols for relapsed or refractory malignancies. This surge in clinical adoption is evidenced by the robust market performance of leading agents; according to Amgen's 'Third Quarter 2024 Financial Results' from October 2024, sales for its bispecific T-cell engager Blincyto increased 49% year-over-year to $327 million, driven primarily by substantial volume growth. This trajectory indicates a decisive market shift toward readily available bispecific modalities as a preferred intervention for managing aggressive B-cell precursors.

Concurrently, the rising focus on Minimal Residual Disease (MRD) monitoring and treatment is transforming patient management from simple symptom control to deep molecular remission strategies. Clinicians are increasingly utilizing highly sensitive next-generation sequencing assays to detect trace leukemic cells that traditional morphological assessments miss, thereby using these insights to guide precise decisions regarding therapy discontinuation or escalation. The growing reliance on this diagnostic approach is highlighted by recent utilization metrics; according to Adaptive Biotechnologies' 'Third Quarter 2024 Financial Results' in November 2024, clinical test volume for its clonoSEQ MRD assay grew 30% year-over-year to approximately 19,600 tests delivered. This escalation underscores the market's pivot toward biomarker-defined endpoints to optimize long-term survival outcomes and minimize unnecessary toxicity in leukemia care.

Key Market Players

  • Novartis AG
  • Bristol-Myers Squibb Company
  • AstraZeneca Plc
  • Gilead Sciences Inc.
  • Pfizer Inc,
  • F. Hoffmann-La Roche AG
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Applied Molecular Genetics Inc.
  • Regeneron Pharmaceuticals, Inc.

Report Scope

In this report, the Global Leukemia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Leukemia Therapeutics Market, By Type

  • Chronic Lymphocytic Leukemia
  • Acute Myeloid Leukemia
  • Chronic Myeloid Leukemia
  • Acute Lymphocytic Leukemia
  • Others

Leukemia Therapeutics Market, By Gender

  • Male
  • Female

Leukemia Therapeutics Market, By Age Groups

  • 0-15
  • 15-30
  • 30-50
  • 50+

Leukemia Therapeutics Market, By Diagnosis

  • Blood Test
  • Biopsy
  • Physical Exam
  • Imaging

Leukemia Therapeutics Market, By Treatment

  • Chemotherapy
  • Stem Cell Transplantation
  • Immunotherapy
  • Targeted Therapy
  • Others

Leukemia Therapeutics Market, By Drugs

  • Tyrosine Kinase Inhibitors
  • Antimetabolites
  • Hormones (Corticosteroids)
  • Monoclonal Antibodies
  • Others

Leukemia Therapeutics Market, By Route of Administration

  • Oral
  • Parenteral

Leukemia Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Leukemia Therapeutics Market.

Available Customizations:

Global Leukemia Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Leukemia Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others)
    • 5.2.2. By Gender (Male, Female)
    • 5.2.3. By Age Groups (0-15, 15-30, 30-50, 50+)
    • 5.2.4. By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging)
    • 5.2.5. By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others)
    • 5.2.6. By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others)
    • 5.2.7. By Route of Administration (Oral, Parenteral)
    • 5.2.8. By Region
    • 5.2.9. By Company (2025)
  • 5.3. Market Map

6. North America Leukemia Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Gender
    • 6.2.3. By Age Groups
    • 6.2.4. By Diagnosis
    • 6.2.5. By Treatment
    • 6.2.6. By Drugs
    • 6.2.7. By Route of Administration
    • 6.2.8. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Leukemia Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Gender
        • 6.3.1.2.3. By Age Groups
        • 6.3.1.2.4. By Diagnosis
        • 6.3.1.2.5. By Treatment
        • 6.3.1.2.6. By Drugs
        • 6.3.1.2.7. By Route of Administration
    • 6.3.2. Canada Leukemia Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Gender
        • 6.3.2.2.3. By Age Groups
        • 6.3.2.2.4. By Diagnosis
        • 6.3.2.2.5. By Treatment
        • 6.3.2.2.6. By Drugs
        • 6.3.2.2.7. By Route of Administration
    • 6.3.3. Mexico Leukemia Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Gender
        • 6.3.3.2.3. By Age Groups
        • 6.3.3.2.4. By Diagnosis
        • 6.3.3.2.5. By Treatment
        • 6.3.3.2.6. By Drugs
        • 6.3.3.2.7. By Route of Administration

7. Europe Leukemia Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Gender
    • 7.2.3. By Age Groups
    • 7.2.4. By Diagnosis
    • 7.2.5. By Treatment
    • 7.2.6. By Drugs
    • 7.2.7. By Route of Administration
    • 7.2.8. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Leukemia Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Gender
        • 7.3.1.2.3. By Age Groups
        • 7.3.1.2.4. By Diagnosis
        • 7.3.1.2.5. By Treatment
        • 7.3.1.2.6. By Drugs
        • 7.3.1.2.7. By Route of Administration
    • 7.3.2. France Leukemia Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Gender
        • 7.3.2.2.3. By Age Groups
        • 7.3.2.2.4. By Diagnosis
        • 7.3.2.2.5. By Treatment
        • 7.3.2.2.6. By Drugs
        • 7.3.2.2.7. By Route of Administration
    • 7.3.3. United Kingdom Leukemia Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Gender
        • 7.3.3.2.3. By Age Groups
        • 7.3.3.2.4. By Diagnosis
        • 7.3.3.2.5. By Treatment
        • 7.3.3.2.6. By Drugs
        • 7.3.3.2.7. By Route of Administration
    • 7.3.4. Italy Leukemia Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Gender
        • 7.3.4.2.3. By Age Groups
        • 7.3.4.2.4. By Diagnosis
        • 7.3.4.2.5. By Treatment
        • 7.3.4.2.6. By Drugs
        • 7.3.4.2.7. By Route of Administration
    • 7.3.5. Spain Leukemia Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Gender
        • 7.3.5.2.3. By Age Groups
        • 7.3.5.2.4. By Diagnosis
        • 7.3.5.2.5. By Treatment
        • 7.3.5.2.6. By Drugs
        • 7.3.5.2.7. By Route of Administration

8. Asia Pacific Leukemia Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Gender
    • 8.2.3. By Age Groups
    • 8.2.4. By Diagnosis
    • 8.2.5. By Treatment
    • 8.2.6. By Drugs
    • 8.2.7. By Route of Administration
    • 8.2.8. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Leukemia Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Gender
        • 8.3.1.2.3. By Age Groups
        • 8.3.1.2.4. By Diagnosis
        • 8.3.1.2.5. By Treatment
        • 8.3.1.2.6. By Drugs
        • 8.3.1.2.7. By Route of Administration
    • 8.3.2. India Leukemia Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Gender
        • 8.3.2.2.3. By Age Groups
        • 8.3.2.2.4. By Diagnosis
        • 8.3.2.2.5. By Treatment
        • 8.3.2.2.6. By Drugs
        • 8.3.2.2.7. By Route of Administration
    • 8.3.3. Japan Leukemia Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Gender
        • 8.3.3.2.3. By Age Groups
        • 8.3.3.2.4. By Diagnosis
        • 8.3.3.2.5. By Treatment
        • 8.3.3.2.6. By Drugs
        • 8.3.3.2.7. By Route of Administration
    • 8.3.4. South Korea Leukemia Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Gender
        • 8.3.4.2.3. By Age Groups
        • 8.3.4.2.4. By Diagnosis
        • 8.3.4.2.5. By Treatment
        • 8.3.4.2.6. By Drugs
        • 8.3.4.2.7. By Route of Administration
    • 8.3.5. Australia Leukemia Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Gender
        • 8.3.5.2.3. By Age Groups
        • 8.3.5.2.4. By Diagnosis
        • 8.3.5.2.5. By Treatment
        • 8.3.5.2.6. By Drugs
        • 8.3.5.2.7. By Route of Administration

9. Middle East & Africa Leukemia Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Gender
    • 9.2.3. By Age Groups
    • 9.2.4. By Diagnosis
    • 9.2.5. By Treatment
    • 9.2.6. By Drugs
    • 9.2.7. By Route of Administration
    • 9.2.8. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Leukemia Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Gender
        • 9.3.1.2.3. By Age Groups
        • 9.3.1.2.4. By Diagnosis
        • 9.3.1.2.5. By Treatment
        • 9.3.1.2.6. By Drugs
        • 9.3.1.2.7. By Route of Administration
    • 9.3.2. UAE Leukemia Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Gender
        • 9.3.2.2.3. By Age Groups
        • 9.3.2.2.4. By Diagnosis
        • 9.3.2.2.5. By Treatment
        • 9.3.2.2.6. By Drugs
        • 9.3.2.2.7. By Route of Administration
    • 9.3.3. South Africa Leukemia Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Gender
        • 9.3.3.2.3. By Age Groups
        • 9.3.3.2.4. By Diagnosis
        • 9.3.3.2.5. By Treatment
        • 9.3.3.2.6. By Drugs
        • 9.3.3.2.7. By Route of Administration

10. South America Leukemia Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Gender
    • 10.2.3. By Age Groups
    • 10.2.4. By Diagnosis
    • 10.2.5. By Treatment
    • 10.2.6. By Drugs
    • 10.2.7. By Route of Administration
    • 10.2.8. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Leukemia Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Gender
        • 10.3.1.2.3. By Age Groups
        • 10.3.1.2.4. By Diagnosis
        • 10.3.1.2.5. By Treatment
        • 10.3.1.2.6. By Drugs
        • 10.3.1.2.7. By Route of Administration
    • 10.3.2. Colombia Leukemia Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Gender
        • 10.3.2.2.3. By Age Groups
        • 10.3.2.2.4. By Diagnosis
        • 10.3.2.2.5. By Treatment
        • 10.3.2.2.6. By Drugs
        • 10.3.2.2.7. By Route of Administration
    • 10.3.3. Argentina Leukemia Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Gender
        • 10.3.3.2.3. By Age Groups
        • 10.3.3.2.4. By Diagnosis
        • 10.3.3.2.5. By Treatment
        • 10.3.3.2.6. By Drugs
        • 10.3.3.2.7. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Leukemia Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bristol-Myers Squibb Company
  • 15.3. AstraZeneca Plc
  • 15.4. Gilead Sciences Inc.
  • 15.5. Pfizer Inc,
  • 15.6. F. Hoffmann-La Roche AG
  • 15.7. AbbVie Inc.
  • 15.8. Takeda Pharmaceutical Company Limited
  • 15.9. Applied Molecular Genetics Inc.
  • 15.10. Regeneron Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer